Bone marrow mononuclear cells (BMMNCs)

Bone marrow mononuclear cells (BMMNCs) are a heterogeneous population of single-nucleus cells derived from the bone marrow, encompassing hematopoietic stem cells, mesenchymal stem cells, monocytes, and lymphocytes (Source: PubMed, PMID: 25650543). While BMMNCs are not a specific molecular target like a receptor or enzyme, they are widely utilized in regenerative medicine as a cellular therapy for treating ischemic and cardiovascular diseases. The therapeutic potential of BMMNCs lies in their ability to migrate to sites of injury and release pro-angiogenic and anti-inflammatory factors that stimulate the body's natural repair mechanisms (Source: NIH, ClinicalTrials.gov). In clinical practice, these cells are typically harvested from a patient's own iliac crest and processed for autologous transplantation to treat conditions such as myocardial infarction or critical limb ischemia. Because they represent a complex mixture of cell types rather than a single protein, they are classified as a cellular product rather than a conventional drug target.

Other names

BMMNCBone marrow-derived mononuclear cellsBM-MNCsBone marrow mononuclear cell fraction

Bone marrow mononuclear cells do not act as a single molecular target; instead, they function as a therapeutic delivery system. Their primary mechanism of action is the paracrine effect, where the cells secrete a variety of cytokines, chemokines, and growth factors (such as VEGF and FGF) that promote neoangiogenesis, reduce apoptosis, and modulate the local inflammatory environment to facilitate tissue regeneration (Source: PubMed, PMID: 21683454). Additionally, specific subpopulations like hematopoietic stem cells can differentiate into various blood cell lineages to restore hematopoiesis (Source: StatPearls, Bone Marrow Aspiration and Biopsy).